Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis

Sarah Chuzi*, Fabio Tavora, Marcelo Cruz, Ricardo Costa, Young Kwang Chae, Benedito A. Carneiro, Francis J. Giles

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

46 Scopus citations

Abstract

Immune checkpoint inhibitors, including cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death-1 (PD-1) inhibitors, represent an effective treatment modality for multiple malignancies. Despite the exciting clinical benefits, checkpoint inhibition is associated with a series of immune-related adverse events (irAEs), many of which can be life-threatening and result in significant treatment delays. Pneumonitis is an adverse event of special interest as it led to treatment-related deaths in early clinical trials. This review summarizes the incidence of pneumonitis during treatment with the different checkpoint inhibitors and discusses the prognostic significance of tumor type. The wide range of clinical, radiographic, and histologic characteristics of checkpoint inhibitor-related pneumonitis is reviewed and followed by guidance on the different management strategies.

Original languageEnglish (US)
Pages (from-to)207-213
Number of pages7
JournalCancer Management and Research
Volume9
DOIs
StatePublished - Jun 14 2017

Keywords

  • Anti-CTLA-4
  • Anti-PD-1
  • Immune checkpoint inhibitors
  • Immune-related adverse event
  • Pneumonitis

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis'. Together they form a unique fingerprint.

Cite this